Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 23, Issue 3, 2007, Pages 381-390

  Persaud, Deborah ^a   Ray, Stuart C ^a   Kajdas, Joleen ^a   Ahonkhai, Aima ^a   Siberry, George K ^a   Ferguson, Kimberly ^a   Ziemniak, Carrie ^a   Quinn, Thomas C ^a,b   Casazza, Joseph P ^b   Zeichner, Steven ^c   Gange, Stephen J ^d   Watson, Douglas C ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; ENVELOPE GENE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURAL GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; EVOLUTION, MOLECULAR; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; PHYLOGENY; RNA, VIRAL; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 34247210615     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0175     Document Type: Article

References (32)

1. Global Summary of the HIV and AIDS epidemic in 2006. Available at http://www.unaids.org, accessed July 2006.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(11):734-739.
3. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337(11):725-733.
4. Luzuriaga K, Wu H, McManus M, et al.: Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol 1999;73(1):362-367.
5. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387(6629):188-191.
6. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94(24):13193-13197.
7. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278(5341):1295-1300.
8. Persaud D, Pierson T, Ruff C, et al.: A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000;105(7):995-1003.
9. Ruff CT, Ray SC, Kwon P, et al.: Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002;76(18):9481-9492.
10. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat Med 2003;9(6):727-728.
11. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278(5341):1291-1295.
12. Chun TW, Nickle DC, Justement JS, et al.: HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005;115(11):3250-3255.
13. Guidelines for the use of antiretroviral agents in pediatric HIV-infection. Available at: http//www.aidsinfo.nih.gov/, accessed 7 April 2005.
14. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at http//www.aidsinfo.nih.gov/, accessed 4 May 2006
15. Luzuriaga K, McManus M, Mofenson L, et al.: A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med 2004;350(24):2471-2480.
16. Persaud D, Siberry GK, Ahonkhai A, et al.: Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 2004;78(2):968-979.
17. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387(6629):183-188.
18. + T cells. Nature 2002;417(6884):95-98.
19. Betts MR, Casazza JP, Patterson BA, et al.: Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol 2000;74(19):9144-9151.
20. Sanchez-Merino V, Nie S, and Luzuriaga K: HIV-1-specific CD8+ T cell responses and viral evolution in women and infants. J Immunol 2005;175(10):6976-6986.
21. Zhang H, Zhou Y, Alcock C, et al.: Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004;78(4):1718-1729.
22. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73(12):10489-10502.
23. Kieffer TL, Finucane MM, Nettles RE, et al.: Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004;189(8):1452-1465.
24. Smith DB, McAllister J, Casino C, and Simmonds P: Virus 'quasispecies': Making a mountain out of a molehill? J Gen Virol 1997;78(Pt.7):1511-1519.
25. Parikh U, Calef C, Larder B, Schinazi RF, and Mellors JW: Mutations in retroviral genes associated with drug resistance. Los Alamos HIV sequence database, 8-2-2003.
26. Luzuriaga K, McManus M, Catalina M, et al.: Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol 2000;74(15):6984-6991.
27. Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191(9):1410-1418.
28. Wolinsky SM, Wike CM, Korber BT, et al.: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992;255(5048):1134-1137.
29. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004;303(5666):2019-2022.
30. Dickover RE, Garratty EM, Plaeger S, and Bryson YJ: Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001;75(5):2194-2203.
31. Scarlatti G, Leitner T, Halapi E, et al.: Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 1993;90(5):1721-1725.
32. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267(5197): 483-489.